Well Referenced

Tag: non-invasive diagnostics

Quantitative and Qualitative Analysis of Circulating Cell-Free DNA Can Be Used as an Adjuvant Tool for Prostate Cancer Screening: A Meta-Analysis

This 2018 meta-analysis evaluates the diagnostic utility of circulating cell-free DNA (cfDNA) in prostate cancer screening. Analyzing data from multiple studies, the research assesses both quantitative (cfDNA concentration) and qualitative (integrity, methylation patterns) aspects of cfDNA. The findings suggest that cfDNA analysis, particularly when combining quantitative and qualitative measures, can

Read More »
June 26, 2025 No Comments

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

This study introduces cfMeDIP-seq, an immunoprecipitation-based method for analyzing methylation patterns in small quantities of circulating cell-free DNA (cfDNA). By profiling the methylomes of cfDNA from plasma samples, the researchers achieved sensitive detection and accurate classification of various cancer types, including early-stage tumors. The approach leverages large-scale, tissue- and cancer-type-specific

Read More »
June 26, 2025 No Comments

Liquid Biopsies for Assessing Metastatic Melanoma Progression

This 2016 study evaluates the utility of liquid biopsies in monitoring metastatic melanoma progression. By analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in blood samples, the research demonstrates that liquid biopsies can provide real-time insights into tumor dynamics, detect emerging resistance mutations, and assess treatment response. The

Read More »
June 26, 2025 No Comments

Cancer DNA in the Circulation: The Liquid Biopsy

This article discusses the emerging field of liquid biopsy, focusing on the detection of circulating tumor DNA (ctDNA) in the bloodstream as a non-invasive method for cancer diagnosis and monitoring. The review highlights the advantages of liquid biopsy over traditional tissue biopsies, including its ability to capture tumor heterogeneity, monitor

Read More »
June 26, 2025 No Comments

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

This review highlights the utility of fecal calprotectin (FC) as a non-invasive biomarker for managing inflammatory bowel diseases (IBD). It describes FC’s role in differentiating IBD from irritable bowel syndrome (IBS), monitoring disease activity, predicting relapses, and evaluating treatment response. Although FC levels correlate well with mucosal healing and histology,

Read More »
June 26, 2025 No Comments

Review article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy

This 2024 systematic review published in Alimentary Pharmacology & Therapeutics (PMID: 39233618) assessed the utility of fecal biomarkers in diagnosing small intestinal damage associated with coeliac disease (CD) and environmental enteropathy (EE). The review analyzed 35 original studies focused on mucosa-derived fecal biomarkers, including calprotectin and antibodies like anti-gliadin, tissue

Read More »
June 26, 2025 No Comments